Skip to main content

Table 4 Number and proportion of patients that reached and not reached G2 at week 5

From: A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients

Visit Statistics BC HNC
SOC Xonrid® + SOC SOC Xonrid® + SOC
WEEK 5 NO G2 5 (27.8%) 10 (55.6%) 11 (68.8%) 13 (65.0%)
G2+ 13 (72.2%) 8 (44.4%) 5 (31.3%) 7 (35.0%)
p-value (Chi-square)   0.09   0.8
Logistic regression Odds ratio   0.31   1.18
95% CI   0.08–1.23   0.29–4.81
p-value   0.1   0.8